The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
REGULATORY
Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
Japan’s all-important reimbursement policy panel on April 9 gave the nod to two new medicines for NHI price listing later this month - Amgen’s cancer agent Imdelltra (tarlatamab) and CSL Behring’s hereditary angioedema (HAE) drug Andembry (garadacimab). The go-ahead was…
To read the full story
Related Article
- CSL’s New HAE Drug Andembry Now Available in Japan
April 21, 2025
- Amgen Rolls Out Imdelltra for SCLC in Japan
April 17, 2025
- Imdelltra, Balversa, 2 More New Drugs Skip March Listing
March 13, 2025
- Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
REGULATORY
- Ruling Bloc, Ishin Reach No Deal on Coverage of OTC-Like Drugs
May 8, 2025
- MHLW to Set Up Special Panel for High-Cost Medical Expense Benefit Program
May 7, 2025
- AMED to Strengthen Coordination Between Projects: New President
May 7, 2025
- Japan Govt OKs Economic Package to Counter US Tariff Impact
April 28, 2025
- ASKA’s Contraceptive, Vabysmo Label Expansion Now in Line for Japan Approval
April 28, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…